Please login to the form below

urothelial carcinoma

This page shows the latest urothelial carcinoma news and features for those working in and with pharma, biotech and healthcare.

Another Tecentriq win for Roche as Avastin combo boosts survival

Tecentriq is currently approved for previously-treated NSCLC patients and also as a second-line therapy for metastatic urothelial carcinoma, a form of bladder cancer.

Latest news

NICE says OK to Keytruda for bladder cancer via the CDF

metastatic urothelial carcinoma in adults who have had platinum-containing chemotherapy. ... Louise Houson, UK managing director for MSD, said: “MSD is really pleased that NICE has recommended pembrolizumab for eligible patients with advanced
MSD’s Keytruda wins bladder cancer indication in Japan

The pharma giant ’s blockbuster has gained a new indication to treat patients with previously treated urothelial carcinoma (UC) that is unresectable with radical surgery and whose disease has progressed following ... chemotherapy. Dr Roy Baynes,
Merck and Pfizer’s PD-L1 drug Bavencio flunks phase III trial

The drug is already approved as a treatment for rare cancer Merkel cell carcinoma and as a second-line therapy for bladder cancer (metastatic urothelial carcinoma), but Pfizer and Merck are
AZ starts pursuit of lung cancer indication for Imfinzi

Imfinzi was approved in the US in May as a second-line treatment after chemotherapy for metastatic urothelial carcinoma - the most common form of bladder cancer - becoming the fifth drug in
Merck, Pfizer cue up first EU launches for PD-L1 drug Bavencio

Bavencio (avelumab) is the first checkpoint inhibitor to be approved in Europe for Merkel cell carcinoma but has already been approved for this indication by the FDA, which also cleared it ... for metastatic urothelial carcinoma (mUC), a form of bladder

More from news
Approximately 2 fully matching, plus 21 partially matching documents found.

Latest Intelligence

Europe vs the US: New drug product approvals

Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Editorial Director – Medical Education – Oxford: Negotiable

Senior Account Manager or AD - Medical Communications: Salary TBC

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Project Manager, Medical Communications, London: Excellent Salary

Medical Writer, e-learning/ training, London: Excellent Salary

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Senior Medical Writer: Great salary and benefits

Project Manager, Medical Communications, Oxford: Excellent Salary

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer: Great salary and bebefits

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Medical Writer - (London, Brighton or Copenhagen): Competitive

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Scientific Director: Great salary and bebefits

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Senior Account Manager – Med Comms – Kent: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...